For most of history, cutting-edge technology and affluence have gone hand-in-hand. The healthcare industry is no exception to the rule.
Share: email Subscribe
Weekly Top Stories Tue, 29 Aug 2023
We have 30 articles this week,# Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®.#Bionoid Pharma Extends Letter of Intent to Acquire Global Alerts Corp. #GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR. #Pyxis Oncology Successfully Completes Acquisition of Apexigen. #APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II. #NorthX Biologics Welcomes Dr Janet Hoogstraate as New CEO Following Merger with Valneva Clinical Trials Manufacturing Unit.
Editor's Choice
1. 
 Telehealth As A Solution For The Medicaid Population
2. 
 Fighting for Mental Health Parity in Healthcare Using Data, Part One.
3. 
 GE Healthcare Launches Digital Tool for AFib
4. 
 AI Biotech Company Genesis Scores $200M to Advance Drug Discovery
5. 
 Empowering Patients to Improve Affordability.
Top 10 M&A Transactions
6. 
 Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®
7. 
 Bionoid Pharma Extends Letter of Intent to Acquire Global Alerts Corp.
8. 
 GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
9. 
 Pyxis Oncology Successfully Completes Acquisition of Apexigen
10. 
 APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II
11. 
 NorthX Biologics Welcomes Dr Janet Hoogstraate as New CEO Following Merger with Valneva Clinical Trials Manufacturing Unit.
12. 
 Cressey & Company Acquires HealthDrive.
13. 
 Grander Closes Acquisition of PolarityTE, Inc. Assets.
14. 
 Transnetyx Expands Offering with Genetic Sequencing Through Acquisition of Laragen.
15. 
 Paradigm Therapeutics Acquires Late Stage “Breakthrough Therapy” Designated Therapy for Treatment of All Subtypes of Epidermolysis Bullosa (EB)
Top 4 Venture Funding
16. 
 Keona Health Raises $7M for Healthcare CRM Integration
17. 
 Venture Firm Questa Capital Scores $397M to Invest in Health Technology.
18. 
 Nursa Secures $80M to Expand Healthcare Staffing Platform
19. 
 Rapport Therapeutics Raises $150 Million in Series B Funding Round and Announces Key Board Appointments to Further Advance Precision Neuromedicine Platform
Top 4 Partnerships Announcements
20. 
 Cancer care company Jasper Health partners with Covet Health
21. 
 PicnicHealth Partners with AstraZeneca to Advance Cancer Datasets.
22. 
 BostonGene, NEC and JIP Form Joint Venture in Japan
23. 
 Synthego and bit.bio Expand Strategic Partnership to Build a Platform for the Development of Safer and More Efficient Genetic Engineering of Human Cells for Cell Therapies
Read More Corporate Development and M&A Activity
Get Featured: Send us your article or blog and we will feature it on our publication, reach over thousands of executives. Click Here.
Editor: Ed Francis

Ed has more than 25 years of management consulting experience and currently is the Global Managing Partner for Infosys Consulting Health and Life Sciences business guiding some of the industry's most prominent health and life sciences organizations through complex transformations.

If you need help with your complex transformation whether it be M&A, digital, or strategic cost reduction or need to bring more innovation into your business strategy Ed can be contacted at Edward.Francis@infosys.com and +1-847-910-6073

Or connect with him at

OTHER ADVISORIES

Health Plan Hospital IT
IT GovHealth
Retail POP Health
Ageing Life Sciences

Advertise with us

We Reach Half Million Decision Makers in:
Healthcare · IT · Retail · Industrial
Advertise with us and reach the right audience.
advertise@distilnfo.com

Contact Us

5760 Legacy Dr, B3-405,
Plano TX 75024
+1 469-270-3311

DistilINFO Publications

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you - saving time and keeping you up to date on your interest areas.

You are receiving this newsletter because you are subscribed to one or more DistilINFO Publications Newsletter/s. If you feel this email was sent by mistake or you want to opt out, you can unsubscribe.

View in browser | Advertise | Contact Us